Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Perioperative Encorafinib+Binimetinib in BRAFV600 Mutant Clinically Detected AJCC Stage III (B/C/D) or Oligometastatic Stage IV Melanoma

NCT05097378 is registered in ClinicalTrials.gov with CCTU- Cancer Theme as lead sponsor.

NCT NCT05097378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05097378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Perioperative Encorafinib+Binimetinib in BRAFV600 Mutant Clinically Detected AJCC Stage III (B/C/D) or Oligometastatic Stage IV Melanoma
Lead sponsor
CCTU- Cancer Theme
Phase
Phase 2
Overall status
Unknown status
Start date
January 1, 2022
Completion date
January 31, 2024
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, melanoma